Researchers are investigating whether HER2-low is a unique subtype of breast cancer, with some studies suggesting it may have distinct characteristics and therapeutic potential. The prevalence and outcomes of HER2-low breast cancer are being examined, particularly in relation to early-stage HER2-negative breast cancer. The classification and treatment of HER2-low breast cancer are still being explored, with ongoing research aiming to better understand its biology and optimal treatment approaches.